Raymond James & Associates’s Bio-Techne TECH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $28.5M | Buy |
356,597
+8,457
| +2% | +$635K | 0.02% | 643 |
|
|
2024
Q2 | $24.9M | Buy |
348,140
+13,953
| +4% | +$1.03M | 0.02% | 664 |
|
|
2024
Q1 | $23.5M | Buy |
334,187
+35,698
| +12% | +$2.55M | 0.02% | 701 |
|
|
2023
Q4 | $23M | Buy |
298,489
+41,929
| +16% | +$2.76M | 0.02% | 676 |
|
|
2023
Q3 | $17.5M | Buy |
256,560
+23,564
| +10% | +$1.86M | 0.01% | 743 |
|
|
2023
Q2 | $19M | Buy |
232,996
+8,596
| +4% | +$691K | 0.02% | 717 |
|
|
2023
Q1 | $16.6M | Buy |
224,400
+29,740
| +15% | +$2.29M | 0.01% | 763 |
|
|
2022
Q4 | $16.1M | Sell |
194,660
-3,372
| -2% | -$268K | 0.01% | 762 |
|
|
2022
Q3 | $14.1M | Buy |
198,032
+16,792
| +9% | +$1.45M | 0.01% | 776 |
|
|
2022
Q2 | $15.7M | Sell |
181,240
-1,636
| -0.9% | -$153K | 0.02% | 728 |
|
|
2022
Q1 | $19.8M | Sell |
182,876
-5,668
| -3% | -$585K | 0.02% | 710 |
|
|
2021
Q4 | $24.4M | Sell |
188,544
-17,540
| -9% | -$2.15M | 0.02% | 647 |
|
|
2021
Q3 | $25M | Sell |
206,084
-16,360
| -7% | -$1.99M | 0.02% | 595 |
|
|
2021
Q2 | $25M | Sell |
222,444
-3,108
| -1% | -$327K | 0.02% | 602 |
|
|
2021
Q1 | $21.5M | Buy |
225,552
+19,084
| +9% | +$1.74M | 0.02% | 639 |
|
|
2020
Q4 | $16.4M | Buy |
206,468
+19,316
| +10% | +$1.4M | 0.02% | 707 |
|
|
2020
Q3 | $11.6M | Buy |
187,152
+27,568
| +17% | +$1.79M | 0.01% | 784 |
|
|
2020
Q2 | $10.5M | Sell |
159,584
-6,112
| -4% | -$366K | 0.01% | 805 |
|
|
2020
Q1 | $7.86M | Buy |
165,696
+40,848
| +33% | +$2.04M | 0.01% | 840 |
|
|
2019
Q4 | $6.85M | Buy |
124,848
+17,900
| +17% | +$939K | 0.01% | 1077 |
|
|
2019
Q3 | $5.23M | Buy |
106,948
+11,532
| +12% | +$578K | 0.01% | 1204 |
|
|
2019
Q2 | $4.97M | Buy |
95,416
+60
| +0.1% | +$3.02K | 0.01% | 1215 |
|
|
2019
Q1 | $4.73M | Sell |
95,356
-3,196
| -3% | -$144K | 0.01% | 1224 |
|
|
2018
Q4 | $3.57M | Sell |
98,552
-2,692
| -3% | -$112K | 0.01% | 1276 |
|
|
2018
Q3 | $5.17M | Buy |
101,244
+1,540
| +2% | +$68.2K | 0.01% | 1199 |
|
|
2018
Q2 | $3.69M | Buy |
99,704
+42,380
| +74% | +$1.62M | 0.01% | 1365 |
|
|
2018
Q1 | $2.17M | Buy |
57,324
+696
| +1% | +$24.6K | ﹤0.01% | 1649 |
|
|
2017
Q4 | $1.83M | Buy |
56,628
+1,240
| +2% | +$39.4K | ﹤0.01% | 1747 |
|
|
2017
Q3 | $1.67M | Buy |
55,388
+14,820
| +37% | +$440K | ﹤0.01% | 1758 |
|
|
2017
Q2 | $1.19M | Sell |
40,568
-360
| -0.9% | -$9.84K | ﹤0.01% | 1908 |
|
|
2017
Q1 | $1.04M | Sell |
40,928
-11,456
| -22% | -$296K | ﹤0.01% | 1957 |
|
|
2016
Q4 | $1.35M | Buy |
52,384
+10,836
| +26% | +$285K | ﹤0.01% | 1752 |
|
|
2016
Q3 | $1.14M | Buy |
41,548
+8
| +0% | +$220 | ﹤0.01% | 1808 |
|
|
2016
Q2 | $1.17M | Sell |
41,540
-11,984
| -22% | -$308K | ﹤0.01% | 1645 |
|
|
2016
Q1 | $1.26M | Buy |
53,524
+720
| +1% | +$15.9K | ﹤0.01% | 1541 |
|
|
2015
Q4 | $1.19M | Sell |
52,804
-788
| -1% | -$18K | ﹤0.01% | 1543 |
|
|
2015
Q3 | $1.24M | Sell |
53,592
-24,172
| -31% | -$606K | 0.01% | 1483 |
|
|
2015
Q2 | $1.91M | Buy |
77,764
+17,824
| +30% | +$445K | 0.01% | 1346 |
|
|
2015
Q1 | $1.5M | Buy |
+59,940
| New | +$1.43M | 0.01% | 1416 |
|
Other funds holding TECH
Raymond James & Associates's TECH Position: Q3 2024 in Review
Raymond James & Associates increased its Bio-Techne (TECH) stake by 2.4% in Q3 2024, buying an estimated $635K and bringing the position to 356,597 shares worth $28.5M. The position accounts for 0.02% of the portfolio, ranked #643.
Raymond James & Associates first reported a position in TECH in Q1 2015 and has held it in 39 quarters since. 562 funds tracked by Wall St. Rank hold TECH as of Q3 2024.
- Raymond James & Associates held 356,597 shares of Bio-Techne worth $28.5M as of Q3 2024.
- Raymond James & Associates bought 8,457 Bio-Techne shares in Q3 2024, an estimated $635K.
- Bio-Techne made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #643 holding.
- Raymond James & Associates first reported a position in Bio-Techne in Q1 2015 and has held it in 39 quarters since.
- 562 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.